AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27699657
Drug: Hydroxychloroquine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine monotherapy (HCQ 400 mg/day)
Trial: 17675277
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg alpha-linolenic acid per day
Trial: 11642634
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 6 months (Group 1)
Trial: 11642634
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 12 months (Group 2)
Trial: 9699707
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus slow-release melatonin
Trial: 2646266
Drug: Megestrol 40
RxNorm normalized name: megestrol 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol 40 mg PO tid
Trial: 2646266
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 1 mg PO tid
Trial: 31220256
Drug: Oral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobial regimen (colistin 2×10^6 IU 4×/day, gentamicin 80 mg 4×/day, fosfomycin 3 g every 72 h)
Trial: 31220256
Drug: Oral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobial regimen
Trial: 23421731
Drug: Amitriptyline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 0.5 mg/kg/d
Trial: 23421731
Drug: Topiramate 25
RxNorm normalized name: topiramate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 25 mg/d increasing up to 100 mg/d
Trial: 16716324
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 3-6 months
Trial: 16716324
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for >6 months
Trial: 16716324
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment overall
Trial: 15477546
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis extract
Trial: 11740797
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with anti-CD4 monoclonal antibodies or anticytokine agents
Trial: 11740797
Drug: T-cell vaccination
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell vaccination and T-cell receptor peptide vaccination targeting autoreactive T cells
Trial: 7888291
Drug: Budesonide and
RxNorm normalized name: Budesonide and formoterol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and Fluticasone (both doses)
Trial: 3283296
Drug: Propranolol-LA (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol-LA (long-acting formulation) at doses of 160, 240, and 320 mg once daily
Trial: 3283296
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol at 80 mg three times daily
Trial: 30298552
Drug: Fluid loading
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid loading (1 g sodium chloride/125 mL of water starting 2.5-h before LBNP)
Trial: 24022566
Drug: L-arginine (20g)
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (20g)
Trial: 20404219
Drug: Amlodipine-valsartan combination
RxNorm normalized name: amlodipine / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine-valsartan combination (5/80 mg and then 10/160 mg)
Trial: 20404219
Drug: Amlodipine-atenolol combination
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-atenolol combination (5/50 mg and then 10/100 mg)
Trial: 20404219
Drug: Amlodipine-valsartan combination
RxNorm normalized name: amlodipine / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine-valsartan combination
Trial: 15802904
Drug: omega3 fatty
RxNorm normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega3 fatty acid‐enhanced supplement
Trial: 15802904
Drug: arginine‐enhanced supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arginine‐enhanced supplement
Trial: 31471180
Drug: TXA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA plus topical and intravenous CSS (Group A)
Trial: 31471180
Drug: TXA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA plus topical CSS only (Group B)
Trial: 31471180
Drug: TXA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA plus intravenous CSS only (Group C)
Trial: 27521928
Drug: Intrauterine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine administration of autologous PBMCs activated by HCG (n=93)
Trial: 27521928
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ET without intrauterine administration) (n=105)
Trial: 20055695
Drug: Twice-weekly tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly tacrolimus ointment
Trial: 20055695
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (vehicle ointment)
Trial: 8744659
Drug: CSE analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSE analgesia with a single subarachnoid injection of 1 mg bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine (total volume, 2.5 mL)
Trial: 8157042
Drug: Intranasal glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal glucagon (1 mg)
Trial: 8243872
Drug: Subcutaneous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous glucagon (0.5 mg)
Trial: 8243872
Drug: Subcutaneous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous glucagon
Trial: 3549893
Drug: Relaxation response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation response technique practiced daily for four to six weeks
Trial: 24719431
Drug: Weekly text-message
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text-message 'check-in' intervention
Trial: 9664766
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate (0.01 mg/kg) and hydroxyzine hydrochloride (1mg/kg) intramuscularly
Trial: 6340971
Drug: Oxaprozin 1200
RxNorm normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaprozin 1200 mg once daily
Trial: 8565037
Drug: Nabumetone 1000
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1000 mg once daily
Trial: 31863182
Drug: Comprehensive multicomponent
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive multicomponent behavioral treatment (Beh)
Trial: 31863182
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavioral treatment and medication management (Comb&MedMgt)
Trial: 11265923
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Comb)
Trial: 25015006
Drug: Clonidine 5
RxNorm normalized name: apraclonidine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 5 μg/kg every 6 hours
Trial: 7019928
Drug: Sisomicin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisomicin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Trial: 7019928
Drug: Tobramycin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Trial: 29344387
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI) 40 U daily or 80 U every other day for 8 weeks, followed by open-label extension with 16, 40 or 80 U RCI 1-3 times/week for 52 weeks.
Trial: 26095443
Drug: Multidisciplinary rehabilitative
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitative care (task-oriented exercises, cognitive-behavioral training, and occupational therapy)
Trial: 17415652
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (including interferon monotherapy, pegylated-interferon monotherapy, consensus-interferon, interferon + ribavirin, pegylated-interferon + ribavirin)
Trial: 15234664
Drug: 15% paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% paromomycin plus 12% methylbenzonium chloride (PR‐MBCL) applied twice daily for 30 days
Trial: 15234664
Drug: 15% paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% paromomycin plus 10% urea (PR‐U) applied twice daily for 30 days
Trial: 11398169
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors as second-line therapy for postmenopausal women with advanced breast cancer progressing during tamoxifen therapy.
Trial: 11398169
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors as first-line therapy in place of tamoxifen.
Trial: 11398169
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors in the prevention of breast cancer and in neoadjuvant and adjuvant treatment of early-stage breast cancer.
Trial: 7989475
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 4 months; mean BMI of treated subgroup: 42.7 ± 4.3 kg/m2.
Trial: 3044515
Drug: Proguanil hydrochloride
RxNorm normalized name: Proguanil Hydrochloride
DrugBank: Proguanil (DB01131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proguanil hydrochloride (100 mg daily according to weight)
Trial: 3044515
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 or 2 tablets daily)
Trial: 21198772
Drug: Propofol (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.35 mg kg(‐1))
Trial: 21198772
Drug: Midazolam (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.035 mg kg(‐1))
Trial: 21198772
Drug: Ketamine (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.30 mg kg(‐1))
Trial: 18220290
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a plus oral placebo for 48 weeks
Trial: 16154709
Drug: Overall cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall cortisol secretion (AUC(G))
Trial: 14583678
Drug: Loperamide (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (24 mg) with Quinidine (800 mg)
Trial: 14583678
Drug: Loperamide (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (24 mg) without Quinidine (placebo)
Trial: 9383184
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg sustained-release verapamil
Trial: 9675624
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg chlorthalidone
Trial: 1388337
Drug: Droperidol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1.25 mg IV)
Trial: 1388337
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg IV)
Trial: 29909432
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 50 mg sildenafil
Trial: 29909432
Drug: Supralingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supralingual administration of 50 mg sildenafil
Trial: 22776958
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human erythropoietin (rEpo) 3 × 3,000 U/kg within 42 h after birth
Trial: 16109111
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg plus naproxen sodium 500 mg
Trial: 16109111
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 500 mg
Trial: 1701802
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 3 injections/week for 13 weeks)
Trial: 1701802
Drug: Intermittent block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent block therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 4 cycles of 5 injections on days 1, 3, 5, 7, and 9)
Trial: 1701802
Drug: Intermittent single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent single-dose therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 6 cycles of 1 injection on day 1)
Trial: 6988175
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg nitrofurantoin plus 150 mg sulphadiazine 3-times daily
Trial: 6988175
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nitrofurantoin plus 500 mg sulphadiazine 3-times daily
Trial: 6988175
Drug: Lower dosage
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dosage group (50 mg nitrofurantoin plus 150 mg sulphadiazine)
Trial: 31176392
Drug: Modified SAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified SAE implants (test group)
Trial: 31176392
Drug: SAE implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SAE implants (control group)
Trial: 25586372
Drug: i-gel prewarmed
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel prewarmed to 42°C (W group)
Trial: 25586372
Drug: i-gel kept
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel kept at room temperature (C group)
Trial: 22181693
Drug: Topical Terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Terbinafine Nail Solution (TNS)
Trial: 20002088
Drug: Warfarin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (10 mg)
Trial: 20002088
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of all five drugs
Trial: 17155989
Drug: Treatment Preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Preference
Trial: 2502251
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution containing L-alanine and glucose
Trial: 2502251
Drug: Standard glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose based oral rehydration solution
Trial: 30551161
Drug: Long-term monitoring
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term monitoring (3-monthly urinalysis)
Trial: 23596809
Drug: Xiaoaiping Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoaiping Injection (XAP) plus best supportive treatment (BST)
Trial: 23596809
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive treatment (BST)
Trial: 22005564
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western therapy + Modified Liang‐Ge San (group L)
Trial: 22005564
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western therapy only (group X)
Trial: 16915119
Drug: Intra-arterial reteplase
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial reteplase (0.5, 1, 1.5, and 2 units) and intravenous abciximab (0.25 mg/kg bolus followed by 0.125 mg/kg/min)
Trial: 16915119
Drug: Intra-arterial reteplase
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial reteplase and intravenous abciximab
Trial: 14669038
Drug: i.m. corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. corticosteroid injection
Trial: 23946326
Drug: varenicline (1mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varenicline (1mg, twice per day for 12 weeks)
Trial: 22498504
Drug: Preservative-free levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free levocabastine 0.05% ophthalmic solution
Trial: 22498504
Drug: Preserved levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preserved levocabastine 0.05% ophthalmic suspension
Trial: 17717030
Drug: Cinacalcet (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (25 mg/day titrated up to 100 mg/day)
Trial: 11008927
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplements for 1 year
Trial: 11008927
Drug: Low erythrocyte
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low erythrocyte magnesium levels (< 2.3 mmol/L)
Trial: 6313557
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: local tumor irradiation (approximately 4,000 cGy) combined with 'one-time' irradiation of the upper and lower half of the body, midplane dose averaging 880 cGy.
Trial: 6313557
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: two half-body irradiation treatments through anterior-posterior fields, average dose of 800 cGy given in two fractions (600 and 200 cGy).
Trial: 20055782
Drug: Erdosteine (5-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (5-8 mg/kg/day)
Trial: 18807725
Drug: Bee-venom therapy
RxNorm normalized name: honey bee venom
DrugBank: Apis mellifera venom (DB10955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee-venom therapy combined with Methotrexate, Sulfasalazine, and Meloxicam (3 months treatment)
Trial: 18807725
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Methotrexate, Sulfasalazine, Meloxicam)
Trial: 19366302
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (Levemir)
Trial: 10797151
Drug: DS of
RxNorm normalized name: l-alkaloids of belladonna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS of 600 ml
Trial: 19284179
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of valerian
Trial: 11156086
Drug: Thoracoscopic, internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracoscopic, internal intercostal nerve block with 3 cc of 0.5% bupivacain at T2, T3, and T4 intercostal levels
Trial: 9362354
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) KIU initially, followed by 5 x 10(5) KIU/h infusion)
Trial: 19143194
Drug: Amlodipine (normodipine)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (normodipine) administered as monotherapy for 12 weeks
Trial: 15814391
Drug: Transcervical Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical Foley catheters (Size 16F, 30 ml balloon)
Trial: 10492406
Drug: Ropivacaine (8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (8.0 ml of 1.0% ropivacaine with 50 IU/ml hyaluronidase)
Trial: 10492406
Drug: Bupivacaine (8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (8.0 ml of 0.75% bupivacaine with 50 IU/ml hyaluronidase)
Trial: 1706910
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (84 micrograms administered in each nostril twice a day for 7 days)
Trial: 1706910
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered in each nostril twice a day for 7 days)